Effect of M2 muscarinic receptor blockade in rats with haloperidol-produced catatonic syndrome.
Dagaev
S G
SG
Laboratory of Biochemistry, Institute of Toxicology, Russian Ministry of Health, St. Petersburg.
Fil'ko
O A
OA
Kubarskaya
L G
LG
Khrabrova
A V
AV
Mukovskii
L A
LA
Glukhova
R I
RI
Sanotskii
V I
VI
Dolgo-Saburov
V B
VB
D000818:Animals; D002375:Catalepsy / Q000139:chemically induced / Q000209:etiology*; D003517:Cyclopentanes / Q000494:pharmacology; D003959:Diamines / Q000494:pharmacology; D004298:Dopamine / Q000378:metabolism; D006220:Haloperidol; D008297:Male; D008333:Mandelic Acids / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D043585:Receptor, Muscarinic M2 / Q000037:antagonists & inhibitors* / Q000502:physiology*; D013577:Syndrome; D014282:Trihexyphenidyl / Q000494:pharmacology
D003517:Cyclopentanes; D003959:Diamines; D008333:Mandelic Acids; D018727:Muscarinic Antagonists; D010880:Piperidines; D043585:Receptor, Muscarinic M2; C492521:pentifin; C016215:amedin; D014282:Trihexyphenidyl; D006220:Haloperidol; C054938:methoctramine; D004298:Dopamine